Merger and Acquisition Deals and Alliances of 2013

Date: August 1, 2014
Pages: 200
Price:
US$ 1,495.00
License [?]:
Publisher: CurrentPartnering
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), CD-ROM Mail Delivery, E-mail Delivery (Word)
ID: ME769EDDB50EN
Leaflet:

Download PDF Leaflet

Merger and Acquisition Deals and Alliances of 2013
The Merger and Acquisition Deals and Alliances of 2013 provides comprehensive understanding and unprecedented access to the M&A deals and agreements entered into by the worlds leading healthcare companies during 2013.

Using these reports, dealmakers will effectively and efficiently gain insight into the M&A activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.

The initial chapters of this report provide an orientation of 2013’s M&A dealmaking and business activities.

Chapter 1 provides an overview of the trends in M&A dealmaking during 2013.

Chapter 2 provides a review of the leading M&A deals during 2013. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active biopharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2013 M&A deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 4 provides a comprehensive directory of all M&A deals announced during 2013.

The chapter is organized by company A-Z. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma M&A dealmaking during 2013.

In conclusion, this report provides everything a prospective M&A dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2013.
CHAPTER 1 – TRENDS IN M&A DEALMAKING DURING 2013

1.1. Bigpharma dealmaking activity

CHAPTER 2 – LEADING M&A DEALS DURING 2013

2.1. Introduction
2.2. Top deals by value during 2013

CHAPTER 3 – BIGPHARMA M&A DEALS DURING 2013

3.1. Introduction
3.2. How to use bigpharma M&A deals
3.3. Bigpharma M&A company profiles for 2013
Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene

CSL

Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson

CHAPTER 4 – M&A DEALS DIRECTORY 2013

4.1. Introduction
4.2. Company A-Z

ABOUT WILDWOOD VENTURES

Current Partnering
Current Agreements
Current Reports
Recent titles from CurrentPartnering
Order Form – Reports

TABLE OF FIGURES

Figure 1: Bigpharma – top 50 – January to December 2013
Figure 2: Bigpharma deal frequency – 2013
Dental Deals and Alliances of 2013 US$ 1,495.00 Aug, 2014 · 200 pages
Dermatology Deals and Alliances of 2013 US$ 1,495.00 Aug, 2014 · 200 pages
Diagnostics Deals and Alliances of 2013 US$ 1,495.00 Aug, 2014 · 200 pages
Drug Delivery Deals and Alliances of 2013 US$ 1,495.00 Aug, 2014 · 200 pages
Gastrointestinal Deals and Alliances of 2013 US$ 1,495.00 Aug, 2014 · 200 pages

Ask Your Question

Merger and Acquisition Deals and Alliances of 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: